Intensive blood pressure lowering reduces chronic kidney disease patients’ risks of dying prematurely or developing cardiovascular disease, according to results from a recent clinical trial published in the Journal of the American Society of Nephrology.
Researchers analyzed information from the Systolic Blood Pressure Intervention Trial (SPRINT), sponsored by the National Institutes of Health. SPRINT, which enrolled individuals 50 years or older with systolic blood pressure of ≥130 mm Hg and at least one additional cardiovascular disease risk factor, compared targeting a systolic blood pressure to <120 mm Hg vs. <140 mm Hg for preventing cardiovascular complications and early death. The benefits of the lower target were apparent almost a year before the study was initially planned to end.
Other articles about SPRINT trial results
- Intensive blood pressure control can reduce risk of left ventricular hypertrophy
- Tighter blood pressure control may save more than 100,000 lives each year in the US
- Use caution when lowering blood pressure targets in CKD patients
In their subgroup analyses, Alfred K. Cheung, MD, from the University of Utah and his colleagues found that individuals who had CKD at the start of the study experienced similar benefits as those without CKD. After a median follow-up of 3.3 years for 1,330 CKD patients in the intensive group and 1,316 in the standard group, the composite cardiovascular outcome occurred in 112 and 131 participants, respectively, translating to a 19% reduction in risk for intensive-group participants. The composite cardiovascular outcome included heart attack, acute coronary syndrome, acute decompensated heart failure, stroke, or heart-related death. Also, there were 70 deaths from any cause in the intensive group compared with 95 in the standard group, for a 28% reduction in risk.
The team found that older participants 75 or older benefited at least as much as those who were younger within this CKD subgroup. There was a slightly faster decline in kidney function in the intensive group, but no increase in kidney events (such as kidney failure) or serious adverse events.
“In people with CKD, lowering systolic blood pressure beyond the conventional goal reduced the risks of heart disease and death, but slightly hastened the decline in kidney function that often accompanies aging,” said Cheung. He noted that these findings come from the largest randomized trial to date on the effects of blood pressure in patients with CKD.